BRAF Gene and Melanoma: Back to the Future.
Antineoplastic Agents
/ administration & dosage
Cell Cycle
Chemotherapy, Adjuvant
Clinical Trials as Topic
DNA Mutational Analysis
Drug Resistance, Neoplasm
/ genetics
Extracellular Signal-Regulated MAP Kinases
/ metabolism
Female
Humans
Immunohistochemistry
Immunotherapy
MAP Kinase Signaling System
Male
Medical Oncology
/ trends
Melanoma
/ genetics
Mutation
Neoplasm Metastasis
Neoplasm Recurrence, Local
/ drug therapy
Protein Kinase Inhibitors
/ pharmacology
Proto-Oncogene Proteins B-raf
/ genetics
Recurrence
Skin Neoplasms
/ genetics
BRAF mutation
immunotherapy
melanoma
targeted therapy
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
27 Mar 2021
27 Mar 2021
Historique:
received:
09
03
2021
revised:
20
03
2021
accepted:
22
03
2021
entrez:
3
4
2021
pubmed:
4
4
2021
medline:
9
7
2021
Statut:
epublish
Résumé
As widely acknowledged, 40-50% of all melanoma patients harbour an activating BRAF mutation (mostly BRAF V600E). The identification of the RAS-RAF-MEK-ERK (MAP kinase) signalling pathway and its targeting has represented a valuable milestone for the advanced and, more recently, for the completely resected stage III and IV melanoma therapy management. However, despite progress in BRAF-mutant melanoma treatment, the two different approaches approved so far for metastatic disease, immunotherapy and BRAF+MEK inhibitors, allow a 5-year survival of no more than 60%, and most patients relapse during treatment due to acquired mechanisms of resistance. Deep insight into BRAF gene biology is fundamental to describe the acquired resistance mechanisms (primary and secondary) and to understand the molecular pathways that are now being investigated in preclinical and clinical studies with the aim of improving outcomes in BRAF-mutant patients.
Identifiants
pubmed: 33801689
pii: ijms22073474
doi: 10.3390/ijms22073474
pmc: PMC8037827
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Protein Kinase Inhibitors
0
BRAF protein, human
EC 2.7.11.1
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
Extracellular Signal-Regulated MAP Kinases
EC 2.7.11.24
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Références
Clin Epigenetics. 2020 Feb 10;12(1):24
pubmed: 32041674
Nat Med. 2019 Jun;25(6):941-946
pubmed: 31171878
Cancer Treat Rev. 2003 Aug;29(4):241-52
pubmed: 12927565
Cells. 2020 Jan 07;9(1):
pubmed: 31936151
Clin Cancer Res. 2015 Apr 1;21(7):1639-51
pubmed: 25589619
NPJ Syst Biol Appl. 2017 Jun 2;3:14
pubmed: 28649441
Sci Rep. 2017 Mar 29;7(1):495
pubmed: 28356599
Arch Pathol Lab Med. 2012 Nov;136(11):1385-91
pubmed: 22332713
Int J Clin Exp Pathol. 2015 Jul 01;8(7):8487-93
pubmed: 26339422
J Invest Dermatol. 2004 Feb;122(2):337-41
pubmed: 15009714
Cell. 2012 Jul 6;150(1):12-27
pubmed: 22770212
Nat Rev Mol Cell Biol. 2006 Jul;7(7):517-28
pubmed: 16829982
Acta Derm Venereol. 2016 Jun 15;96(5):630-4
pubmed: 26695089
Nat Med. 2019 Jun;25(6):879-882
pubmed: 31171877
Nat Commun. 2014;5:3116
pubmed: 24445538
Am Soc Clin Oncol Educ Book. 2019 Jan;39:185-195
pubmed: 31099635
Cancer Res. 2019 Jun 1;79(11):2947-2961
pubmed: 30987999
Mol Cancer Res. 2014 Mar;12(3):447-63
pubmed: 24425783
N Engl J Med. 2019 Aug 15;381(7):626-636
pubmed: 31166680
Lancet. 2020 Jun 13;395(10240):1835-1844
pubmed: 32534646
Ther Adv Med Oncol. 2020 Jun 19;12:1758835920925219
pubmed: 32612709
Br J Cancer. 2013 May 28;108(10):2164-71
pubmed: 23579220
Oncogene. 2003 May 19;22(20):3113-22
pubmed: 12789288
Cancer Discov. 2016 Apr;6(4):353-67
pubmed: 26658964
Clin Cancer Res. 2019 Feb 15;25(4):1272-1279
pubmed: 30630828
PLoS One. 2015 Mar 19;10(3):e0120232
pubmed: 25789737
Nature. 2012 Jul 26;487(7408):500-4
pubmed: 22763439
Lancet Oncol. 2019 Sep;20(9):1239-1251
pubmed: 31345627
Mol Cancer. 2018 Jan 17;17(1):8
pubmed: 29343260
Biochim Biophys Acta. 2007 Aug;1773(8):1263-84
pubmed: 17126425
Hum Pathol. 2015 Feb;46(2):169-75
pubmed: 25442222
Cold Spring Harb Perspect Med. 2012 Dec 01;2(12):a006676
pubmed: 23209177
Cancer Res. 2006 Aug 15;66(16):8109-15
pubmed: 16912188
Melanoma Res. 2015 Jun;25(3):239-45
pubmed: 25746039
J Surg Oncol. 2019 Jan;119(2):175-186
pubmed: 30548543
Virchows Arch. 2019 Apr;474(4):421-432
pubmed: 30747264
Int J Oncol. 2020 Jun;56(6):1429-1441
pubmed: 32236593
Cancer Chemother Pharmacol. 2013 May;71(5):1191-9
pubmed: 23423489
J Cutan Pathol. 2014 Sep;41(9):724-32
pubmed: 24917033
Crit Rev Oncol Hematol. 2020 Dec;156:103118
pubmed: 33038627
Ann Oncol. 2018 Aug 1;29(8):1843-1852
pubmed: 30010756
Nat Commun. 2014 Dec 02;5:5694
pubmed: 25452114
Transl Lung Cancer Res. 2018 Dec;7(6):661-667
pubmed: 30505710
Oncogene. 2007 May 14;26(22):3159-71
pubmed: 17496913
Cancer Cell. 2015 Jan 12;27(1):85-96
pubmed: 25500121
Future Oncol. 2016 Nov;12(22):2531-2534
pubmed: 27715206
Oncol Res Treat. 2017;40(7-8):430-434
pubmed: 28728158
JCO Precis Oncol. 2018;2018:
pubmed: 30234181
Clin Cancer Res. 2017 Sep 1;23(17):5238-5245
pubmed: 28536307
Lancet Oncol. 2020 Mar;21(3):358-372
pubmed: 32007138
Nat Commun. 2019 Nov 13;10(1):5143
pubmed: 31723142
J Clin Oncol. 2018 Feb 1;36(4):383-390
pubmed: 28671856
Nature. 2019 Nov;575(7783):545-550
pubmed: 31581174
Cell. 2016 Mar 24;165(1):35-44
pubmed: 26997480
Pigment Cell Melanoma Res. 2011 Apr;24(2):345-51
pubmed: 21324100
Curr Oncol Rep. 2016 Jun;18(6):34
pubmed: 27106898
Structure. 2015 Aug 4;23(8):1382-1393
pubmed: 26165597
Sci Transl Med. 2017 May 31;9(392):
pubmed: 28566428
N Engl J Med. 2017 Nov 9;377(19):1824-1835
pubmed: 28891423
Am J Pathol. 2002 Jul;161(1):229-37
pubmed: 12107107
Lancet Oncol. 2018 Oct;19(10):1315-1327
pubmed: 30219628
J Clin Oncol. 2020 Nov 20;38(33):3925-3936
pubmed: 32946353
J Invest Dermatol. 2010 Feb;130(2):620-2
pubmed: 19798057
Cancer J. 2012 Mar-Apr;18(2):142-7
pubmed: 22453015
N Engl J Med. 2011 Jun 30;364(26):2507-16
pubmed: 21639808
Sci Adv. 2015 Jun 12;1(5):e1500447
pubmed: 26601204
Mol Cancer Ther. 2014 Oct;13(10):2253-63
pubmed: 25122067
Oncogenesis. 2018 Sep 20;7(9):72
pubmed: 30237495
BMC Cancer. 2016 Nov 18;16(1):905
pubmed: 27863476
Lancet Oncol. 2016 Sep;17(9):1248-60
pubmed: 27480103
Clin Epigenetics. 2017 Apr 4;9:34
pubmed: 28396701
N Engl J Med. 2017 Nov 9;377(19):1813-1823
pubmed: 28891408
Cell Rep. 2019 Oct 15;29(3):573-588.e7
pubmed: 31618628
N Engl J Med. 2015 Jan 1;372(1):30-9
pubmed: 25399551
Nature. 2002 Jun 27;417(6892):949-54
pubmed: 12068308
J Clin Oncol. 2011 Apr 1;29(10):1239-46
pubmed: 21343559
Lancet Oncol. 2020 Nov;21(11):1465-1477
pubmed: 32961119
J Mol Diagn. 2013 Nov;15(6):790-5
pubmed: 23994118
N Engl J Med. 2016 Nov 10;375(19):1845-1855
pubmed: 27717298
Cell Prolif. 2003 Jun;36(3):131-49
pubmed: 12814430
Nat Rev Cancer. 2017 Jan 27;17(2):93-115
pubmed: 28127048
Lancet Oncol. 2018 Apr;19(4):510-520
pubmed: 29477665
PLoS One. 2017 Oct 5;12(10):e0185862
pubmed: 28982154
Cell. 2015 Jun 18;161(7):1681-96
pubmed: 26091043
Cell. 2002 Jul 26;110(2):163-75
pubmed: 12150925
BMC Cancer. 2015 Oct 24;15:779
pubmed: 26498038
Cancer Res. 2010 Jul 1;70(13):5213-9
pubmed: 20551059
Cancers (Basel). 2020 Mar 21;12(3):
pubmed: 32245160
Clin Cancer Res. 2018 Dec 15;24(24):6107-6109
pubmed: 30042206
Clin Cancer Res. 2009 Mar 1;15(5):1801-7
pubmed: 19223509
Nat Commun. 2014 Dec 15;5:5712
pubmed: 25502142
Oncogene. 2018 Jun;37(24):3275-3289
pubmed: 29551771
N Engl J Med. 2018 May 10;378(19):1789-1801
pubmed: 29658430
ISRN Oncol. 2012;2012:546927
pubmed: 22720169
Crit Rev Eukaryot Gene Expr. 2014;24(2):151-61
pubmed: 24940768
Int J Mol Sci. 2019 Dec 08;20(24):
pubmed: 31817947
N Engl J Med. 2019 Oct 17;381(16):1535-1546
pubmed: 31562797
Front Immunol. 2019 May 09;10:1023
pubmed: 31156623
Pigment Cell Melanoma Res. 2019 Jul;32(4):603-606
pubmed: 30801911
Virchows Arch. 2018 Sep;473(3):371-377
pubmed: 29926184
Cold Spring Harb Perspect Biol. 2012 Sep 01;4(9):a011189
pubmed: 22952397
Mod Pathol. 2018 Jan;31(1):24-38
pubmed: 29148538
Lancet. 2020 May 16;395(10236):1558-1568
pubmed: 32416781
J Clin Oncol. 2019 Nov 20;37(33):3142-3151
pubmed: 31580757
Clin Cancer Res. 2019 Dec 15;25(24):7351-7362
pubmed: 31530631
Biol Cell. 2001 Sep;93(1-2):53-62
pubmed: 11730323
Melanoma Res. 2006 Apr;16(2):197-200
pubmed: 16567976
Ann Oncol. 2015 Oct;26(10):2173-9
pubmed: 26202595
Expert Opin Pharmacother. 2021 Feb;22(3):351-361
pubmed: 33030382
Am J Surg Pathol. 2013 Jan;37(1):61-5
pubmed: 23026937
Ann Dermatol Venereol. 2021 Feb 9;:
pubmed: 33579557
Expert Rev Anticancer Ther. 2020 Jan;20(1):53-62
pubmed: 31903803
Cell. 2004 Mar 19;116(6):855-67
pubmed: 15035987
Nucleic Acids Res. 2017 Jan 4;45(D1):D777-D783
pubmed: 27899578
Eur J Cancer. 2020 Feb;126:33-44
pubmed: 31901705
Int J Oncol. 2018 Sep;53(3):1149-1159
pubmed: 29956724
Oncol Lett. 2017 Sep;14(3):3601-3605
pubmed: 28927118
Genes (Basel). 2020 May 15;11(5):
pubmed: 32429325
J Clin Oncol. 2018 Dec 10;36(35):3441-3449
pubmed: 30343620
Trends Genet. 2014 Aug;30(8):356-63
pubmed: 24932742
Cancer Chemother Pharmacol. 2020 Apr;85(4):673-683
pubmed: 32062691
Cold Spring Harb Perspect Biol. 2012 Nov 01;4(11):
pubmed: 23125017
Clin Cancer Res. 2013 Sep 1;19(17):4868-78
pubmed: 23833299
Lancet Oncol. 2018 May;19(5):603-615
pubmed: 29573941
Mol Cancer. 2019 Nov 4;18(1):153
pubmed: 31684958
Br J Cancer. 2010 Jun 8;102(12):1724-30
pubmed: 20531415
J Immunother Cancer. 2019 Jul 12;7(1):180
pubmed: 31300034
J Clin Oncol. 2002 Nov 1;20(21):4368-80
pubmed: 12409337
JAMA Oncol. 2018 Oct 1;4(10):1382-1388
pubmed: 30073321
Pharmaceuticals (Basel). 2020 Nov 24;13(12):
pubmed: 33255177
J Mol Diagn. 2013 Jan;15(1):94-100
pubmed: 23159108
Ann Oncol. 2020 Sep;31(9):1148-1159
pubmed: 32569725
Cancer Discov. 2012 Sep;2(9):791-7
pubmed: 22798288
Int J Mol Sci. 2019 Mar 25;20(6):
pubmed: 30934534
Acta Oncol. 2020 Jul;59(7):833-844
pubmed: 32285732
Semin Cancer Biol. 2018 Aug;51:80-88
pubmed: 29074395
Nature. 2013 Aug 22;500(7463):415-21
pubmed: 23945592
Leukemia. 2004 Feb;18(2):189-218
pubmed: 14737178
PLoS One. 2013;8(1):e53733
pubmed: 23326492
Cancers (Basel). 2020 May 06;12(5):
pubmed: 32384792
J Transl Med. 2010 Jul 14;8:67
pubmed: 20630094
Clin Cancer Res. 2012 Jun 15;18(12):3242-9
pubmed: 22535154
J Eur Acad Dermatol Venereol. 2020 Aug;34(8):e393-e395
pubmed: 32056293
Clin Chem. 2006 Apr;52(4):557-8
pubmed: 16595822
Int J Cancer. 2018 May 15;142(10):2139-2152
pubmed: 29243224
Cancer Cell. 2015 Feb 9;27(2):240-56
pubmed: 25600339
Br J Cancer. 2017 Sep 26;117(7):1026-1035
pubmed: 28787433
Cancer Res. 2017 Jul 1;77(13):3502-3512
pubmed: 28512244
Oncotarget. 2015 Dec 8;6(39):42008-18
pubmed: 26524482
J Dtsch Dermatol Ges. 2018 Apr;16(4):405-414
pubmed: 29512873
Pharmacol Res. 2018 Oct;136:151-159
pubmed: 30145328
Proc Natl Acad Sci U S A. 2016 Feb 2;113(5):1250-5
pubmed: 26787892
J Natl Cancer Inst. 2010 Apr 7;102(7):493-501
pubmed: 20179267
BMC Cancer. 2014 Jul 19;14:519
pubmed: 25037456
Clin Cancer Res. 2015 Apr 1;21(7):1652-64
pubmed: 25617424
Clin Cancer Res. 2019 Oct 1;25(19):5735-5742
pubmed: 30992297
Oncotarget. 2017 Mar 7;8(10):16367-16386
pubmed: 28146421
J Hematol Oncol. 2019 Sep 6;12(1):93
pubmed: 31492199
N Engl J Med. 2014 Nov 13;371(20):1877-88
pubmed: 25265492
Melanoma Res. 2017 Dec;27(6):527-535
pubmed: 28858076
Cancer Immunol Res. 2014 Jul;2(7):632-42
pubmed: 24838938
N Engl J Med. 2014 Nov 13;371(20):1867-76
pubmed: 25265494
JAMA Dermatol. 2015 Apr;151(4):410-6
pubmed: 25588152
Ann Surg Oncol. 2018 Aug;25(8):2105-2110
pubmed: 29850954
Nature. 2017 Aug 10;548(7666):234-238
pubmed: 28783719